Understanding immune cells in Crohn's disease after surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the role of interleukin-23-responsive immune cell subsets in patients with Crohn's disease who experience postoperative recurrence. It aims to identify the mechanisms behind the unchecked proliferation of proinflammatory cells that contribute to the disease's recurrence after surgical intervention. By analyzing patients who show signs of recurrence during routine endoscopy, the study seeks to enhance the understanding of Crohn's disease pathophysiology and inform future therapeutic strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \>/= 18 years;
* Male or non-pregnant, non-lactating females;
* Patients with postoperative recurrence at routine endoscopy 6-24 months following resection, defined by presence of ulcerations (endoscopic Rutgeerts' score \>i2a) in the neoterminal ileum;
* In the opinion of the investigator, the subject is capable of understanding and complying with protocol requirements;
* The subject signs and dates a written informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion Criteria:

* Any conditions (eg, history of alcohol or substance abuse, or lack of compliance) which, in the opinion of the investigator, may interfere with the patient's ability to comply with study procedures;
* Any condition in which one of the potential treatments are contraindicated in the opinion of the investigator (eg, cardiac failure class 3-4 according to the New York Heart Association \[NYHA\], multiple sclerosis, active infections).
* Received any investigational drug in the past 30 days or 5 half-lives, whichever is longer.
* Currently participating or planning to participate in a study involving an investigational product.
* Active or planned pregnancy during the study.
* Prior diagnosis of dysplasia in the colon (excluding in resected adenomas).
* History of malignancy in the 3 years prior to randomization except for non-melanoma skin cancer.
* Received a biologic treatment between surgery and first endoscopy.
* Positive Clostridium difficile toxin B in faeces. Patients who test positive can be treated per local practice and still enter the study if no longer than 4 weeks after the screening visit, they test negative for Clostridium difficile toxin B.
* Presence of a stoma without ileocolonic anastomosis or pouch.
* Active perianal abscess or draining fistula
* ALT or AST \> 3x the upper limit of normal measured at screening
* Increased risk of bleeding: coagulation disorder, use of anticoagulants and DOACs

Where it's running

• Mount Sinai
  Toronto, Ontario, Canada Recruiting
• Amsterdam UMC
  Amsterdam, North Holland, Netherlands Recruiting

Study contacts

• Study coordinator: Lotte Oldenburg
• Email: l.oldenburg@amsterdamumc.nl
• Phone: 020 444 1125

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Iron treatment for children and young adults with Crohn’s disease and iron deficiency anemia

  This study tests how different iron treatment approaches work for kids and young adults with Crohn’s disease and iron deficiency anemia.

  Recruiting Phase 4 Weill Medical College of Cornell University · New York, New York · NCT07925450

• Autologous intestinal organoids applied to Crohn's ulcers in a first-in-human dose-escalation study

  This early-phase study tests a patient-derived intestinal organoid therapy (ATORM-C) delivered during colonoscopy to Crohn’s ulcers to see if it is safe and tolerable and to get a sense of healing.

  Recruiting Phase 1 Organoidsciences LTD. · Seoul · NCT07822087

• SL-325 in Crohn's Disease: a phase 2 test for adults with moderate to severe disease

  This phase 2 study tests SL-325 against placebo in adults with moderately to severely active Crohn's disease to see if it helps improve symptoms and disease activity.

  Recruiting Phase 2 Shattuck Labs, Inc. · Little Rock, Arkansas and 19 other locations · NCT07753850

• Advanced therapies for moderately to severely active Crohn's disease or ulcerative colitis in adults

  This study tests combinations of risankizumab with either trosunilimab or ABBV-701 in adults with moderately to severely active Crohn's disease or ulcerative colitis.

  Recruiting at 66 sites Phase 2 AbbVie · Dothan, Alabama and 65 other locations · NCT07697456

• Stop PPI in active IBD: can you safely go without acid-suppressing meds?

  This study tests whether people with inflammatory bowel disease who have been on proton pump inhibitors can stop taking them and still manage their symptoms.

  Recruiting Phase 4 University of Nottingham · Nottingham · NCT07691138

• Tabellvi for moderate to severe Crohn's disease in Chinese adults

  This real-world, single-arm study tests Tabellvi® (adalimumab) in Chinese adults with moderate to severe Crohn's disease to see how often side effects occur and whether many patients reach remission by week 26.

  Recruiting Phase 4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Fuyang, Anhui and 6 other locations · NCT07663526

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.